GlassScriptPhysician profile
Tony Mathews
NPI 1508201559
$1,202.94
in general payments reported to CMS, 2019-2025
7 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.89 · 2023: $22.64 · 2024: $659 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.07 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $359.15 | 2024-2025 | Wegovy, Ozempic |
| Amgen INC. | $257.63 | 2022-2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2025 | |
| Abbott Laboratories | $139.09 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Sanofi-Aventis U.S. LLC | $131.37 | 2024 | |
| Lilly USA, LLC | $121.30 | 2024 | Zepbound |
| Medtronic, INC. | $44.40 | 2023-2024 | Inpen Smart Insulin Delivery System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.